Product Complaint Form Instructions



Similar documents
11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

Recommendations to Transplant Centres Performing Cord Blood Transplants. Why Choosing the Right Thaw Method Could Save a Patient s Life

FormsNet3 SM Cord Blood Bank Training Guide

CHAPTER 5 SHIPPING PROCEDURES

Public Cord Blood Banking at the National Cord Blood Program (NCBP)

Cord Blood Advisory Group: Organization and Highlights (from November 2013 meeting)

Cord Blood: Thawing & Infusion Practical Methods

Cord Blood Banking and Biologic License Application (BLA) November 19, 2010

US Regulations for Import and Export of Cell Therapy Products

Guidance for Industry and FDA Staff

Human Umbilical Cord Blood CD34 + Progenitor Cell Care Manual

Table of Contents. FACT Quality Handbook, Second Edition. Table of Contents

The Cord Blood Industry and Be The Match

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Jennifer Collins, RN Quality Liaison Ann & Robert H. Lurie Children's Hospital of Chicago

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Response to Public Comments for the 7 th edition of Standards for Cellular Therapy Services

Hematopoietic stem and progenitor cell transplants: regulation and accreditation

2. TRansport ARRANGEMENTS Flight arrangements Ground transport arrangements... 5

Preamble. 1. If it is necessary, are you willing to receive follow up questions to help clarify any answers to the survey questions?

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

14.0 Stem Cell Laboratory Services

Comparability of Cord Blood Units

Licensing Your Cord Blood

Background: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?

Improving Quality in Cellular Therapy with FACT Accreditation. The Foundation for the Accreditation of Cellular Therapy

CMC Writing for IND Applications. David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop

CBS National Public Cord Blood Bank. Did you donate your cord blood?

[DOCKET NO.96N-0002] DRAFT

CHAPTER 3 COLLECTION PROCEDURES

Hippocrates, Cords and Quality

HRSA Update to the Advisory Council on Blood Stem Cell Transplantation. Shelley Grant September 15, 2014

Economics of Cord Blood Banking. Michael Boo NMDP Be The Match September 11, 2015

Umbilical Cord Blood Transplantation

NMDP s Collaborative Approach to ISBT 128 Implementation. ISCT 20th Annual Meeting Paris, France Mayra Basiri April/26/2014

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between

Australian Bone Marrow Donor Registry PROTECTING YOUR PRIVACY OUR PRIVACY POLICY

GAO NATIONAL CORD BLOOD INVENTORY. Practices for Increasing Availability for Transplants and Related Challenges. Report to Congressional Committees

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

Cord Blood Licensure. Session 2C: Advanced Cell Therapies April 11, 2013

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

Guidance for Industry

FDA Cell Therapy Liaison Meeting, 10 September

Transmedcon Ahmedabad, Gujarat November 14-16, 2014

Program Report to the Advisory Council on Blood Stem Cell Transplantation. Shelley Grant September 11, 2015

Canadian Blood Services National Public Cord Blood Bank

Guidance for Industry

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

CLIENT AGREEMENT. Copyright 2014 MiracleCord Inc. All rights reserved.

Le norme internazionali NetCord-FACT: linee guida per la qualità nel bancaggio del sangue cordonale

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

The Danish Bone Marrow Donor Registry DBMDR

General Information about Donating Blood Stem Cells

Guide to Regulatory Requirements for the Procurement of Human Tissues and Cells intended for Human Application

CPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD

hematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.

The Power & Potential of Cord Blood

SAVE A LIFE... BY GIVING LIFE!

PACT Web Seminar July 19, 2007

Summary Basis for Regulatory Action

Blood cells are vital to the human body

Overview of OneMatch, including the OneMatch Public Cord Blood Bank

Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Guidance for Industry

OUR JOURNEY THROUGH THE YEARS

Cord Blood Collec*on Training. Michigan Blood Cord Blood Bank 2011

Blood-Forming Stem Cell Transplants

CordBank Limited, which supplies processing and services with respect to cord blood. CordBank is referred to in this contract as CordBank or we ;

CHAPTER 7 QUALITY ASSESSMENT

Kathie Viers-City of Hope Eric Presson- Baylor Health Care Systems Jennifer Christian-Markay Cancer Center

INTERNATIONAL STANDARDS FOR CORD BLOOD COLLECTION, BANKING, AND RELEASE FOR ADMINISTRATION

The Power & Potential of Cord Blood

Processing & Utilization of Cord Blood for Transplant

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Inspection Guide for WMDA reviewers

APPLICATION FOR SITE INSPECTION Eye Bank Association of America

Human CD4+T Cell Care Manual

UMBILICAL CORD BLOOD COLLECTION

STEM CELL THERAPEUTIC OUTCOMES DATABASE

SUBPART 58-5 Hematopoietic Progenitor Cell Banks

Q: Why is there a need for people to join the Be The Match Registry?

Cord Blood Stem Cell Transplantation

MEMORANDUM. BLA CMC Review of Original Submission. HPC, Cord Blood. LifeSouth Community Blood Center Inc.

4. Cell Separation - Clinical Research Products

Children s Research Management System (CRMS) Version 3.0. Children s Hospital Colorado Research Institute Training Guide April 2015

Cord Blood Collections for the Texas Cord Blood Bank. Obstetrical Providers Training Module

Tracking Customer Service Using LSRTIS Phone Log. The purpose of this document is to provide guidance for logging information in the LSRTIS Phone Log.

Blood, Plasma, and Cellular Blood Components INTRODUCTION

CDC-Lipid Standardization Program. Laboratory Data Collection System (LDCS) Instruction Manual

Donation of Umbilical Cord Blood. A precious life offer. for everyone!

MEMORANDUM. BLA CMC Review of Original Submission HPC, Cord Blood. Duke University of School of Medicine, Carolina Cord Blood Bank

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Site visit inspection report on compliance with HTA minimum standards. SCI Oxford. HTA licensing number Licensed for the

Public Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden

New Zealand Bone Marrow Donor Registry

INTERNATIONAL STANDARDS FOR CORD BLOOD COLLECTION, BANKING, AND RELEASE FOR ADMINISTRATION

Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank

CORD BLOOD BANKING FAQ

Transcription:

Product Complaint Form Instructions Note: Product Complaint Definition: Failure/possible failure of a drug (includes biological products) to meet any of its specifications. This includes complaints that may potentially impact the safety, quality, identity, purity, or potency of the product. This form should be completed when a transplant center identifies problem(s) with the product as indicated in the definition above. The form should be completed as soon as possible after identifying the problem(s), but within three business days. The form should be completed for a single product (including all bags of that product). If more than one product is received that has the same problem(s), a separate Complaint form should be completed for each product. Key Field: Sequence Number: This field will be auto-populated by the system. Make note of the sequence number in any external tracking mechanism you have to easily locate the form again. Key Field: Date Received: This field will be auto-populated by the system as the date the form is first processed. Question 1: Date Problem was discovered: Indicate the date that the problem(s) reported with this product was first noticed (in M/D/YYYY format). This field is required. Recipient Information Question 2: NMDP Recipient ID (RID): (if applicable) Enter the NMDP-generated Recipient ID number (RID). This number should be in XXX- XXX-X format. This is the unique recipient identifier that is assigned by NMDP at time of Formal Search activation. The RID must be entered without dashes. This is an optional field. Question 3: Local Recipient ID: (optional) If your center assigns an institution-specific ID for recipients, you may enter that here. This field is not required. Document Title: Form 3010 Product Complaint Form Instructions Page 1 of 6

Product Information Question 4: Date product was received: Enter the date that your center took responsibility of the product (in M/D/YYYY format). If you are refusing to accept this product based on quality reasons, indicate the date that you inspected the product to determine its suitabilty. This field is required. Question 5: Date of product collection: Enter the date the product was collected (in M/D/YYYY format). Collection date should be noted in the accompanying records sent with the product. This field is required. Question 6: Product type received by transplant center: Indicate the product for which this form is being completed. This field is required. Mark only one. If the product is not listed, check other and specify the product type in question 7. If the product was Cord Blood, continue with question 8. For all other products, continue with question 22. Questions 7: Specify other product type using ISBT-128 naming conventions: Indicate the other product type (required if question 6 is Other ) and continue with question 22. Product Identification (HPC, Cord Blood) Note: Questions 8-21 may only be completed if the Product type indicated in question 6 is HPC, Cord Blood (Umbilical Cord Blood). Questions 8-9: Cord Blood Registry: and Specify other Cord Blood Registry: Select the appropriate Cord Blood Registry from the dropdown. If the bank that provided the product is not working through a registry, select Bank doesn t report through a registry. If you do not see the appropriate registry listed, please select Other and specify the other registry in question 9. Questions 10-11: Cord Blood Bank: and Specify other Cord Blood Bank: This question must be answered if question 8 is answered NMDP or Bank doesn t report through a registry. Select the appropriate cord blood bank from the dropdown list. If Other is selected in question 10, specify cord blood bank in question 11. Questions 12-16: NMDP Cord Blood Unit ID (CBUID): (if applicable) and Non-NMDP Registry Cord Blood Unit ID (Coop Reg CBUID): (if applicable) and Local Cord Blood Unit ID: (if applicable) and Is the Local Cord Blood Unit ID also the ISBT-128 number? Enter the cord blood unit ID in the appropriate question(s). Provide as many IDs as are known to facilitate investigation. One of questions 13-15 is required to be entered if Document Title: Form 3010 Product Complaint Form Instructions Page 2 of 6

question 6 is answered HPC, Cord Blood (Umbilical Cord Blood). The NMDP CBU ID is required if question 8 indicates that the unit was facilitated by the NMDP. If question 15 is answered, then question 16 is also required to be answered. Note: If there are multiple bags of this product, questions 12-16 can be repeated up to 5 times to report all bags of the product by clicking ADD NEW. Question 17: Was the CBU requested through the NMDP? Select whether the cord blood unit was requested through the NMDP. This field is required. Question 18: Is the CBU licensed by the U.S. Food and Drug Administration? Select whether the cord blood unit is licensed by the FDA. This field is required. If No is selected in question 18, specify IND sponsor in question 19. Questions 19-21: Specify the IND Sponsor: and Specify IND Sponsor name: and Specify IND number: (if known) If the cord blood unit was not licensed by the FDA, indicate whether shipment was facilitated under the NMDP IND or another Sponsor s IND. If Other is selected in question 19, specify IND sponsor name and IND number in questions 20-21. Donor Identification (HPC, Marrow; HPC, Apheresis; TC, Apheresis; TC, Whole Blood; Other) Question 22: ID on product bag: Enter the ID on the product bag. Questions 23-24: NMDP Donor ID (DID): and Non-NMDP Unrelated Donor ID (Coop Reg Donor ID): (if applicable): Enter the NMDP Donor ID or the Non-NMDP Unrelated Donor ID. One of these fields is required if question 6 is not HPC, Cord Blood (Umbilical Cord Blood). Note: If there are multiple bags of this product, questions 22-24 can be repeated up to 5 times to report all bags of the product by clicking ADD NEW. Document Title: Form 3010 Product Complaint Form Instructions Page 3 of 6

Product Complaint Information For Questions 25-32, report all issues that apply to this complaint. Each question must be answered either yes or no. Question 25: Was the product bag cracked/broken? Indicate if the product bag was damaged. This field is required. Question 26: Did the cryopreserved product arrive thawed? If the product was intended to be frozen upon arrival, indicate if it arrived thawed. If the product was not intended to arrive frozen (e.g., HPC, Apheresis or HPC, Marrow), indicate not applicable. This field is required. Question 27: Was there a problem with transport or handling? Indicate if there was a problem with transport or handling of the product. This field is required. Question 28: Was there a problem with product labeling and/or accompanying records? Indicate if there was a problem with product labeling or the records that accompany the product at shipment. This field is required. Question 29: Was the product contaminated? Indicate if the product was contaminated. Describe the nature of the contamination in question 35 (e.g., positive sterility result). This field is required. Question 30: Was there a problem with product appearance (e.g., clots, color, particulates)? Indicate if there was a problem with the appearance of the product. Describe the appearance in question 35. This field is required. Question 31: Was the cell count/viability significantly lower than expected or agreed upon? Indicate if the cell count or viability was significantly lower than expected or agreed upon. This field is required. Question 32: Was there a problem of a nature not listed in questions 25-31? If there was another problem that was not listed in any of the above fields, indicate yes here and describe the problem in question 35. Questions 33-34: When was the problem/complaint discovered? Indicate whether the problem was discovered when the product was received or after receipt (e.g., at product thaw). If after thaw, indicate at what point the problem was discovered in Q34. This field is required. Document Title: Form 3010 Product Complaint Form Instructions Page 4 of 6

Question 35: Describe problem/complaint and when and how it was discovered: Enter a description of the problem and impact to the transplant center, transplant schedule, and/or recipient. Include details such as location and approximate size of crack, color, temperature data, preliminary culture results, etc., as applicable to the problem, and describe how the problem was discovered. Applicable pictures and laboratory data can be sent to TMS@nmdp.org. Do not repeat information that was already entered elsewhere in the form. This question is required for all products. Note that this field is limited to 1000 characters, so the description should be as succinct as possible, while still describing the event in enough detail so that a reviewer can determine the severity of the incident. Question 36: Describe immediate action taken: Describe any immediate action taken to contain or correct the problem. This question is required for all products. If no action was taken, none is an acceptable response. Note that this field is limited to 1000 characters, so the description should be as succinct as possible, while still describing the event in enough detail so that a reviewer can determine the severity of the incident. Question 37: Was product infused? Indicate if the product was infused. This field is required. Question 38: Date of infusion: Enter the date the product was infused (in M/D/YYYY format). This question is required for all products that were infused. If the product was infused overnight, indicate the date the infusion started as the date of infusion. Question 39: Was there a serious recipient adverse event caused by, or probably caused by, the product? Indicate whether this product may have caused a serious recipient adverse event. If yes, also complete a Form 3001 Adverse Event Form. Person Completing Form First Name: and Last Name: The First Name and Last Name of the person logged in to complete the form will be populated by the system. There is no action required by the user. These questions will populate each time the form is opened and saved. Date: This question will be populated by the system each time the form is opened and saved. There is no action required by the user. Document Title: Form 3010 Product Complaint Form Instructions Page 5 of 6

Preferred method of contact: (phone number or email address) Enter information for the best way to contact the person completing the form. This information will be used if there are questions about the product complaint that is being reported. This question is required for all products. Queries Review and Form Processing Once the Preferred method of contact field has been completed, proceed to the Queries Review page. Answer any queries and process the form. The Process button will submit the form and display a form process page. The Process/Next button will submit the current form and will open a new Form 3010 for entry. NMDP Review Section Questions 44-53: To Be Completed By NMDP/CIBMTR Reviewer This section will be completed by NMDP/CIBMTR. Do not enter any information into this section. The form cannot be processed if any of the fields have been completed. When Form 3010 is processed by a user at the transplant center and there are no errors, the form will go to Review status. NMDP will review your submission and document the results of the review on the same form, should you wish to maintain it in your files. Once the form has been reviewed by NMDP/CIBMTR the form will go to Complete status. At this time, an email will be send to the cord blood bank, and to the IND sponsor notifying them of this complaint. In the event the form is in Complete status and data is changed by the transplant center and the form is saved or processed, the information contained in the review section will be removed by the system. Document Title: Form 3010 Product Complaint Form Instructions Page 6 of 6